Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
10 août 2022 09h00 HE
|
Arcutis Biotherapeutics, Inc.
Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated steroid-free cream that rapidly...
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
29 juil. 2022 16h05 HE
|
Arcutis Biotherapeutics, Inc.
First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque...
Plaque Psoriasis Pipeline Analysis of 75+ Companies | DelveInsight
18 juil. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 18, 2022 (GLOBE NEWSWIRE) -- Plaque Psoriasis Pipeline Analysis of 75+ Companies | DelveInsight Plaque psoriasis pipeline constitutes 75+ key companies continuously working...
Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
11 juil. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studiesIf approved, roflumilast cream would be...
Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight
19 avr. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, April 19, 2022 (GLOBE NEWSWIRE) -- Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight Plaque Psoriasis is the most common type of psoriasis...
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
25 mars 2022 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment (IGA) success (40%) at week 8 compared to vehicle (7%),...
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
20 déc. 2021 07h59 HE
|
Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study
20 oct. 2021 16h05 HE
|
Zai Lab Limited
Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque...
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
11 mai 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier...
Psoriasis Drugs Market To Reach USD 39.00 Billion By 2027 | Reports And Data
22 janv. 2020 08h52 HE
|
Reports and Data
New York, Jan. 22, 2020 (GLOBE NEWSWIRE) -- The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027, according to a new report by Reports and Data. Psoriasis can be defined...